NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
TAEST16001 Phase II
Phase 2 mab active
Quick answer
NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy) for Soft Tissue Sarcoma is a Phase 2 program (mab) at PRECISION BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PRECISION BIOSCIENCES INC
- Indication
- Soft Tissue Sarcoma
- Phase
- Phase 2
- Modality
- mab
- Status
- active